Aspire Biopharma to Enact 1-for-30 Reverse Stock Split to Meet Nasdaq Listing Rules
ASBP sits 33% above its 52-week low of $0.164 on elevated volume (10× avg).
Summary
Aspire Biopharma Holdings, Inc. has announced it will effect a 1-for-30 reverse stock split, effective May 11, 2026, to regain compliance with Nasdaq's minimum bid price requirement. This significant reverse split follows the company's recent 10-K/A filing which highlighted "going concern" issues, indicating severe financial distress. The move also comes shortly after a PRE 14A filing for highly dilutive warrant issuances, suggesting a need for capital despite a contradictory $5 million share repurchase program announced just days prior. While necessary to maintain its listing, a reverse split of this magnitude often signals underlying business challenges and can lead to further downward pressure on the stock as it does not fundamentally improve the company's operations or financial health. Traders should monitor the stock's performance post-split and the impact of the upcoming warrant issuances.
At the time of this announcement, ASBP was trading at $0.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.16 to $35.01. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Access Newswire.